Physician profile
Antonio Valone
NPI 1336598713
$2,633.82
in general payments reported to CMS, 2019-2025
17 companies · $341 in 2025
The $341 reported for 2025 was less than what a typical Nuclear Cardiology provider received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $93.41 · 2021: $331 · 2022: $683 · 2023: $745 · 2024: $333 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,418.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $469.31 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $362.31 | 2020-2023 | Lifevest |
| Impulse Dynamics (USA) INC. | $294.42 | 2023-2025 | Optimizer, Optimizer |
| Atricure, INC. | $213.41 | 2022 | |
| Boston Scientific Corporation | $207.45 | 2023-2025 | Watchman Flx, Watchman |
| E.R. Squibb & Sons, L.L.C. | $144.37 | 2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $143.51 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $130.41 | 2022-2024 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $124.99 | 2023 | Uptravi, Opsumit |
| Biotronik INC. | $111.45 | 2022 | |
| Pfizer INC. | $108.01 | 2019 | |
| Amgen INC. | $101.51 | 2024-2025 | Repatha, Repatha |
| Kestra Medical Technology Services, INC. | $75.04 | 2023-2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.76 | 2023-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $36.03 | 2023-2024 | Xarelto |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.98 | 2024 | Verquvo |
| Edwards Lifesciences Corporation | $22.86 | 2025 | Sapien 3 Ultra Resilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Valone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.